Aurobindo subsidiary teams up with MSD for biologics manufacturing

6 June 2024

Aurobindo Pharma's (BSE: 524804) wholly-owned subsidiary, TheraNym Biologics Private, has signed a Master Service Agreement (MSA) with Merck Sharpe & Dohme (MSD).

TheraNym will invest around $119 million in a new facility to produce products for MSD, the trading name for US pharm giant Merck & Co (NYSE: MRK) outside of the USA and Canada.

The share price of the Indian company soared on the announcement. The deal marks a significant advancement for Aurobindo in the biologics manufacturing sector, and will help the Indian major explore contract manufacturing operations (CMO) for biologicals.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK